Metformin: From diabetes to cancer to prolongation of life
Pharmacological Research · 2024-10 · 208 · 107367
DOI: 10.1016/j.phrs.2024.107367 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacological Research, 2024-10. Verfasst von Cesare R Sirtori und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center of Dyslipidemias, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; Centro E. Grossi Paoletti, Department of Pharmacological and Biom…. Hauptthemen laut MEDLINE: Metformin, Neoplasms, Hypoglycemic Agents, Diabetes Mellitus. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
The metformin molecule dates back to over a century, but its clinical use started in the '50s. Since then, its use in diabetics has grown constantly, with over 150 million users today. The therapeutic profile also expanded, with improved understanding of novel mechanisms. Metformin has a major activity on insulin resistance, by acting on the insulin receptors and mitochondria, most likely by activation of the adenosine monophosphate-activated kinase. These and associated mechanisms lead to significant lipid lowering and body weight loss. An anti-cancer action has come up in recent years, with mechanisms partly dependent on the mitochondrial activity and also on phosphatidylinositol 3-kinase resistance occurring in some malignant tumors. The potential of metformin to raise life-length is the object of large ongoing studies and of several basic and clinical investigations. The present review article will attempt to investigate the basic mechanisms behind these diverse activities and the potential clinical benefits. Metformin may act on transcriptional activity by histone modification, DNA methylation and miRNAs. An activity on age-associated inflammation (inflammaging) may occur via activation of the nuclear factor erythroid 2 related factor and changes in gut microbiota. A senolytic activity, leading to reduction of cells with the senescent associated secretory phenotype, may be crucial in lifespan prolongation as well as in ancillary properties in age-associated diseases, such as Parkinson's disease. Telomere prolongation may be related to the activity on mitochondrial respiratory factor 1 and on peroxisome gamma proliferator coactivator 1-alpha. Very recent observations on the potential to act on the most severe neurological disorders, such as amyotrophic lateral sclerosis and frontotemporal dementia, have raised considerable hope.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Dyslipidemias, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; Centro E. Grossi Paoletti, Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy. Ele…
- Center of Dyslipidemias, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; Centro E. Grossi Paoletti, Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy.
Zitieren
APA
Sirtori, C. R., Castiglione, S., & Pavanello, C. (2024). Metformin: From diabetes to cancer to prolongation of life. Pharmacological Research, 208, 107367. https://doi.org/10.1016/j.phrs.2024.107367
Vancouver
Sirtori CR, Castiglione S, Pavanello C. Metformin: From diabetes to cancer to prolongation of life. Pharmacological Research. 2024;208:107367. doi:10.1016/j.phrs.2024.107367
BibTeX
@article{Sirtori2024,
author = {Sirtori, Cesare R and Castiglione, Sofia and Pavanello, Chiara},
title = {Metformin: From diabetes to cancer to prolongation of life},
journal = {Pharmacological Research},
year = {2024},
volume = {208},
pages = {107367},
doi = {10.1016/j.phrs.2024.107367}
}
EUVIMED